Clinical Trial Update: CD123 Redirected T Cells for AML in Pediatric Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial of CD123-targeted T cells for acute myeloid leukemia in pediatric patients and those with relapse or refractory disease has been terminated. The u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD123 Redirected T Cells

Snippet

Sponsor: University of Pennsylvania | Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Pediatric | Phase 1 | Status: TERMINATED